MedTrace Logo

Evaluation of Astaxanthin Properties on Anti-fatigue

NCT06593535 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-09-19

No results posted yet for this study

Summary

Ten young, healthy, physically active male college students were crossed over for AST or placebo supplements randomized into placebo or AST trials and orally consumed placebo or AST (28 mg/d) supplements for four days. Short-term AST supplementation enhanced endurance performance and effectively reversed cycling challenge-induced muscle damage and lipid peroxidation.

Conditions

  • Healthy Volunteer

Interventions

OTHER

Placebo (Placebo trial)

The Placebo capsule supplement was taken for 4 days (7 capsules per day)

OTHER

Astaxanthin (AST trial)

The AST capsule supplement was taken for 4 days, with a daily dosage of 28 mg of AST (equivalent to 7 capsules per day, each containing 4 mg of AST).

Sponsors & Collaborators

  • National Science and Technology Council

    collaborator FED

  • China Medical University, China

    collaborator OTHER

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Jung-Piao Tsao · China Medical University, China

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-25
Primary Completion
2022-07-17
Completion
2022-09-20

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06593535 on ClinicalTrials.gov